Fny Investment Advisers, LLC Viking Therapeutics, Inc. Call Options Transaction History

Fny Investment Advisers, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 05, 2024	BUY	$47.39 - $80.2 $7,487 - $12,671	158 Added 112.06%	299 $15,000
Q1 2024 May 02, 2024	BUY	$17.4 - $94.5 $2,453 - $13,324	141 New	141 $11,000
Q3 2019 Oct 25, 2019	SELL	$6.55 - $8.6 $1,179 - $1,548	-180 Reduced 86.54%	28 $0
Q2 2019 Jul 24, 2019	SELL	$7.67 - $10.63 $2,469 - $3,422	-322 Reduced 60.75%	208 $1,000
Q1 2019 Apr 17, 2019	BUY	$7.58 - $9.94 $2,122 - $2,783	280 Added 112.0%	530 $5,000
Q3 2018 Oct 29, 2018	BUY	$9.7 - $19.65 $2,085 - $4,224	215 Added 614.29%	250 $4,000
Q2 2018 Jul 18, 2018	BUY	$3.88 - $12.74 $135 - $445	35 New	35 $0

442

63.3M

6.23M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.83B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Fny Investment Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Fny Investment Advisers, LLC with notifications on news.